This antitumorigenic effect is mediated through the activation of cyclin-dependent kinase inhibitors specifically p21 & p27, which disrupt the action of mitogenic growth factors such as insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF), while simultaneously enhancing the tumour-suppressive effects of transforming growth factor-beta (TGF-)
They can also provide guidance on the frequency and dosage of these injections
The mechanisms of TB-500 are still being investigated, but known actions of TB4 include: Binding as an actin-binding protein to inhibit the polymerization of globular actin (G-actin) into filamentous actin (F-actin), known as actin sequestration, which results in higher G-actin levels and increased cellular motility [23, 24] TB4s ability to increase cellular motility may help progenitor cells to reach sites of injury and initiate tissue recovery [25]
This response is further amplified by the release of pro-inflammatory factors, resulting in sustained inflammation that exacerbates tissue damage and may contribute to decompensation [271, 320]
Absorption: Expect oral antihistamines to take longer to start working
